CNBX (CNBX Pharmaceuticals) Additional Paid-In Capital : $22.49 Mil(As of Feb. 2025)

View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Additional Paid-In Capital?

CNBX Pharmaceuticals's quarterly additional paid-in capital stayed the same from Aug. 2024 ($22.47 Mil) to Nov. 2024 ($22.47 Mil) but then increased from Nov. 2024 ($22.47 Mil) to Feb. 2025 ($22.49 Mil).

CNBX Pharmaceuticals's annual additional paid-in capital increased from Aug. 2022 ($18.03 Mil) to Aug. 2023 ($22.24 Mil) and increased from Aug. 2023 ($22.24 Mil) to Aug. 2024 ($22.47 Mil).

CNBX Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for CNBX Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Additional Paid-In Capital Chart

CNBX Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Additional Paid-In Capital

Get a 7-Day Free Trial

15.37

17.06

18.03

22.24

22.47

CNBX Pharmaceuticals Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Additional Paid-In Capital	Get a 7-Day Free Trial															22.40	22.44	22.47	22.47	22.49

CNBX Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

CNBX Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

CNBX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814

Website

https://www.cnbxpharma.com

CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.

Executives

Cannabics Inc.	10 percent owner	108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills	director, officer: President, CEO, CFO
North American Mining Corp	10 percent owner	6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford	director, officer: Vice-President, Secretary